Pm Headache Tablet, Film Coated
NDC 51316-674
Product Information
Pm Headache (acetaminophen, aspirin, diphenhydramine citrate) is a OTC MONOGRAPH DRUG-approved product labeled by Cvs Woonsocket Prescription Center, Incorporated. This medication is typically used as a anti-inflammatory agents. It is supplied as a blue tablet, film coated for oral administration. This product entry covers the primary NDC 51316-674 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
674
Code Structure Chart
Product Details
What is NDC 51316-674?
What are the uses of this product?
What are Active Ingredients of this product?
- ACETAMINOPHEN 250 mg/1 - Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
- ASPIRIN 250 mg/1 - The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
- DIPHENHYDRAMINE CITRATE 38 mg/1 - A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ACETAMINOPHEN (UNII: 362O9ITL9D)
- ACETAMINOPHEN (UNII: 362O9ITL9D) (Active Moiety)
- ASPIRIN (UNII: R16CO5Y76E)
- ASPIRIN (UNII: R16CO5Y76E) (Active Moiety)
- DIPHENHYDRAMINE CITRATE (UNII: 4OD433S209)
- DIPHENHYDRAMINE (UNII: 8GTS82S83M) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- STARCH, CORN (UNII: O8232NY3SJ)
- CROSPOVIDONE, UNSPECIFIED (UNII: 2S7830E561)
- FD&C BLUE NO. 1 ALUMINUM LAKE (UNII: J9EQA3S2JM)
- HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
- MALTODEXTRIN (UNII: 7CVR7L4A2D)
- MEDIUM-CHAIN TRIGLYCERIDES (UNII: C9H2L21V7U)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- POLYDEXTROSE (UNII: VH2XOU12IE)
- POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)
- SODIUM LAURYL SULFATE (UNII: 368GB5141J)
- SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
- SODIUM SULFATE (UNII: 0YPR65R21J)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FERRIC OXIDE YELLOW (UNII: EX438O2MRT)
- ZINC STEARATE (UNII: H92E6QA4FV)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1593110 - acetaminophen 250 MG / aspirin 250 MG / diphenhydrAMINE citrate 38 MG Oral Tablet
- RxCUI: 1593110 - acetaminophen 250 MG / aspirin 250 MG / diphenhydramine citrate 38 MG Oral Tablet
- RxCUI: 1593110 - APAP 250 MG / ASA 250 MG / Diphenhydramine Citrate 38 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
- Anti-Inflammatory Agents, Non-Steroidal - [CS]
- Cyclooxygenase Inhibitors - [MoA] (Mechanism of Action)
- Decreased Platelet Aggregation - [PE] (Physiologic Effect)
- Decreased Prostaglandin Production - [PE] (Physiologic Effect)
- Histamine H1 Receptor Antagonists - [MoA] (Mechanism of Action)
- Histamine-1 Receptor Antagonist - [EPC] (Established Pharmacologic Class)
- Nonsteroidal Anti-inflammatory Drug - [EPC] (Established Pharmacologic Class)
- Platelet Aggregation Inhibitor - [EPC] (Established Pharmacologic Class)
* Please review the full disclaimer at the bottom of this page.